Evidence map›Paper›PMID 17235625›Full record

SynthesisGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2006

Gastric cancer screening using the serum pepsinogen test method.

Kazumasa Miki

Registry-linked trialOpen access · bronzeAbstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05224596 (Gastric Cancer Detection by Liquid Biopsy in Peripheral Blood), which is not on this map. Cited by 119 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 5 pooled it
10.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05224596 unknown statusnot on this mapstarted 2021, after this paper: background citation

Gastric Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study

TypeobservationalSponsorShanghai Zhongshan HospitalRan2021 to 2022Enrolled498ConditionsCancerArmsBlood draw and blood-based biomarkers analyses
3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 5 syntheses or guidelines pooled it, 274 citations in OpenAlex.

  1. Pooled it
  2. A non-invasive method for the diagnosis of upper GI diseases.Acta bio-medica : Atenei Parmensis · 2018
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Screening strategies for the early detection of non-cardia gastric cancer in low- to moderate-prevalence regions: Asia-Pacific gastroesophageal cancer congress consensus 2026.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Kazumasa MikiDivision of Gastroenterology and Hepatology, Department of Internal Medicine (Ohmori), School of Medicine, Faculty of Medicine, Toho University, 6-11-1 Ohmori Nishi, Ohta-ku, Tokyo, 143-8541, Japan.
Toho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current status of gastric cancer screening, worldwide, as well as in Japan, using the serum pepsinogen test method, was reviewed. We performed a metaanalysis of sensitivity and specificity results from 42 individual studies (27 population-based screening studies: n = 296 553 and 15 selected groups: n = 4 385). Pooled pairs of sensitivity and false-positive rates (FPr) for pepsinogen I level < or = 70 ng/ml; pepsinogen I/II ratio < or = 3, had a sensitivity of 77%/FPr27%. The positive predictive value varied between 0.77% and 1.25%, and the negative predictive value varied between 99.08% and 99.90%. Therefore, we concluded that the definition of the pepsinogen test should include the pepsinogen I/II ratio, as consistency was obtained for both the population-based studies and the selected groups for those studies that used pepsinogen I serum levels together with the pepsinogen I/II ratio for screening for gastric cancer in high-incidence regions other than Japan. Individuals testing positive for extensive atrophic gastritis by serum pepsinogen levels undergo endoscopic examination to test for the presence of gastric cancer. We should increase the efficacy and cost-effectiveness of the gastric cancer screening system, by the identification of groups, at low-risk, as well as those at high-risk, of developing gastric cancer, using a combination of assays of serum Helicobacter pylori antibody titers and the concentration of pepsinogen I and II. In conclusion, the pepsinogen test method can be used as a screening test for high-risk subjects, rather than as a tool for screening for cancer itself. I hope that this pepsinogen test method will become a world standard for gastric cancer prevention in the near future, in other countries, as well as in Japan.

Indexed as

False Positive ReactionsHumansMass ScreeningPepsinogen APepsinogen CReproducibility of ResultsSensitivity and SpecificityStomach NeoplasmsPepsinogen APepsinogen C

Identifiers

PMID17235625
OpenAlexW1988599811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.